Daniel J. George

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

Alain Ravaud, Robert J. Motzer, Hardev Pandha et al. · New England Journal of Medicine · 2016 · 757 citations

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

Toni K. Choueiri, Susan Halabi, Ben L. Sanford et al. · Journal of Clinical Oncology · 2017 · 707 citations · Full text

Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate

Joel B. Nelson, Sean P. Hedican, Daniel J. George et al. · Nature Medicine · 1995 · 622 citations

Urology, Pathology, Benign Prostatic Hyperplasia +4

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

Toni K. Choueiri, Colin Hessel, Susan Halabi et al. · European Journal of Cancer · 2018 · 392 citations · Full text

Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma

Leigh Ellis, Yan Pan, Gordon K. Smyth et al. · Clinical Cancer Research · 2008 · 299 citations